Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


Articles published in Cancer Chemother Pharmacol

Retrieve available abstracts of 81 articles:
HTML format
Text format



Single Articles


    May 2018
  1. MORCOS PN, Nueesch E, Jaminion F, Guerini E, et al
    Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2018 May 10. pii: 10.1007/s00280-018-3597.
    PubMed     Text format     Abstract available


  2. IMAI H, Minemura H, Sugiyama T, Yamada Y, et al
    Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations.
    Cancer Chemother Pharmacol. 2018 May 8. pii: 10.1007/s00280-018-3596.
    PubMed     Text format     Abstract available


  3. KOBA T, Minami S, Nishijima-Futami Y, Masuhiro K, et al
    Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2018 May 4. pii: 10.1007/s00280-018-3598.
    PubMed     Text format     Abstract available


  4. SMIT EF, Garon EB, Reck M, Cappuzzo F, et al
    Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2018 May 2. pii: 10.1007/s00280-018-3560.
    PubMed     Text format     Abstract available


    April 2018
  5. FUJITA K, Uchida N, Kanai O, Okamura M, et al
    Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
    Cancer Chemother Pharmacol. 2018 Apr 19. pii: 10.1007/s00280-018-3585.
    PubMed     Text format     Abstract available


  6. NIHEI S, Sato J, Harada T, Kuyama S, et al
    Antiproteinuric effects of renin-angiotensin inhibitors in lung cancer patients receiving bevacizumab.
    Cancer Chemother Pharmacol. 2018 Apr 12. pii: 10.1007/s00280-018-3580.
    PubMed     Text format     Abstract available


  7. FUKUSHIMA T, Wakatsuki Y, Kobayashi T, Sonehara K, et al
    Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2018 Apr 11. pii: 10.1007/s00280-018-3573.
    PubMed     Text format     Abstract available


    February 2018
  8. CUI J, Wang MC, Zhang YM, Ren MZ, et al
    Combination of S-1 and gefitinib increases the sensitivity to radiotherapy in lung cancer cells.
    Cancer Chemother Pharmacol. 2018 Feb 26. pii: 10.1007/s00280-018-3539.
    PubMed     Text format     Abstract available


  9. SIENA L, Cipollina C, Di Vincenzo S, Ferraro M, et al
    Electrophilic derivatives of omega-3 fatty acids counteract lung cancer cell growth.
    Cancer Chemother Pharmacol. 2018 Feb 12. pii: 10.1007/s00280-018-3538.
    PubMed     Text format     Abstract available


    January 2018
  10. TAIRA T, Yoh K, Nagase S, Kubota K, et al
    Long-term results of S-1 plus cisplatin with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2018 Jan 31. pii: 10.1007/s00280-018-3530.
    PubMed     Text format     Abstract available


  11. WANG S, Gao A, Liu J, Sun Y, et al
    First-line therapy for advanced non-small cell lung cancer with activating EGFR mutation: is combined EGFR-TKIs and chemotherapy a better choice?
    Cancer Chemother Pharmacol. 2018 Jan 11. pii: 10.1007/s00280-017-3516.
    PubMed     Text format     Abstract available


    December 2017
  12. FEDORCHUK O, Susak Y, Rudyk M, Senchylo N, et al
    Immunological hallmarks of cis-DDP-resistant Lewis lung carcinoma cells.
    Cancer Chemother Pharmacol. 2017 Dec 30. pii: 10.1007/s00280-017-3503.
    PubMed     Text format     Abstract available


  13. KATAOKA Y, Hirano K, Narabayashi T, Hara S, et al
    Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study.
    Cancer Chemother Pharmacol. 2017 Dec 11. pii: 10.1007/s00280-017-3498.
    PubMed     Text format     Abstract available


    November 2017
  14. MASUDA T, Hirano C, Horimasu Y, Nakashima T, et al
    The extent of ground-glass attenuation is a risk factor of chemotherapy-related exacerbation of interstitial lung disease in patients with non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Nov 15. doi: 10.1007/s00280-017-3476.
    PubMed     Text format     Abstract available


  15. SAKURAI R, Tomizawa Y, Yoshii A, Miura Y, et al
    A phase II study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Nov 9. doi: 10.1007/s00280-017-3439.
    PubMed     Text format     Abstract available


  16. SCHMID U, Liesenfeld KH, Fleury A, Dallinger C, et al
    Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
    Cancer Chemother Pharmacol. 2017 Nov 8. doi: 10.1007/s00280-017-3452.
    PubMed     Text format     Abstract available


  17. MURAKAMI S, Saito H, Kondo T, Ito H, et al
    Phase II study of nedaplatin and irinotecan as adjuvant chemotherapy for completely resected non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Nov 7. doi: 10.1007/s00280-017-3460.
    PubMed     Text format     Abstract available


    October 2017
  18. CHEN K, Yu X, Wang H, Huang Z, et al
    Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
    Cancer Chemother Pharmacol. 2017 Oct 24. doi: 10.1007/s00280-017-3464.
    PubMed     Text format     Abstract available


  19. SRINIVASAN G, Sidhu GS, Williamson EA, Jaiswal AS, et al
    Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
    Cancer Chemother Pharmacol. 2017;80:861-867.
    PubMed     Text format     Abstract available


    September 2017
  20. ZHANG H, Hu B, Wang Z, Zhang F, et al
    miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1.
    Cancer Chemother Pharmacol. 2017 Sep 27. doi: 10.1007/s00280-017-3435.
    PubMed     Text format     Abstract available


  21. IKEZAWA Y, Asahina H, Oizumi S, Watanabe M, et al
    A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002).
    Cancer Chemother Pharmacol. 2017 Sep 13. doi: 10.1007/s00280-017-3432.
    PubMed     Text format     Abstract available


  22. SATO J, Morikawa N, Chiba R, Nihei S, et al
    Case series on the association between blood levels and side effects of afatinib maleate.
    Cancer Chemother Pharmacol. 2017;80:545-553.
    PubMed     Text format     Abstract available


    August 2017
  23. REN K, Xu R, Huang J, Zhao J, et al
    Knockdown of long non-coding RNA KCNQ1OT1 depressed chemoresistance to paclitaxel in lung adenocarcinoma.
    Cancer Chemother Pharmacol. 2017;80:243-250.
    PubMed     Text format     Abstract available


    July 2017
  24. IMAI H, Sugiyama T, Tamura T, Minemura H, et al
    A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients.
    Cancer Chemother Pharmacol. 2017 Jul 31. doi: 10.1007/s00280-017-3403.
    PubMed     Text format     Abstract available


  25. KENMOTSU H, Ohde Y, Wakuda K, Nakashima K, et al
    Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Jul 31. doi: 10.1007/s00280-017-3400.
    PubMed     Text format     Abstract available


  26. ZHAO XM, Zhao J, Wu XH, Luo ZG, et al
    Significance of glucocorticoid receptor expression in patients with non-small cell lung cancer treated with pemetrexed-based chemotherapy.
    Cancer Chemother Pharmacol. 2017 Jul 28. doi: 10.1007/s00280-017-3399.
    PubMed     Text format     Abstract available


  27. KIM HK, Heo MH, Lee HS, Sun JM, et al
    Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors.
    Cancer Chemother Pharmacol. 2017 Jul 21. doi: 10.1007/s00280-017-3396.
    PubMed     Text format     Abstract available


  28. SHIROYAMA T, Tamiya M, Minami S, Takata S, et al
    Carboplatin plus weekly nanoparticle albumin-bound paclitaxel in elderly patients with previously untreated advanced squamous non-small-cell lung cancer selected based on Mini Nutritional Assessment short-form scores: a multicenter phase 2 study.
    Cancer Chemother Pharmacol. 2017 Jul 7. doi: 10.1007/s00280-017-3385.
    PubMed     Text format     Abstract available


    June 2017
  29. XU L, Fu Y, Li Y, Han X, et al
    Cisplatin induces expression of drug resistance-related genes through c-jun N-terminal kinase pathway in human lung cancer cells.
    Cancer Chemother Pharmacol. 2017 Jun 8. doi: 10.1007/s00280-017-3355.
    PubMed     Text format     Abstract available


  30. PARK S, Kang BW, Lee SJ, Yoon S, et al
    Clinical significance of systemic chemotherapy after curative resection of metachronous pulmonary metastases from colorectal cancer.
    Cancer Chemother Pharmacol. 2017 Jun 8. doi: 10.1007/s00280-017-3348.
    PubMed     Text format     Abstract available


  31. ASPESLAGH S, Shailubhai K, Bahleda R, Gazzah A, et al
    Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors.
    Cancer Chemother Pharmacol. 2017;79:1257-1265.
    PubMed     Text format     Abstract available


    May 2017
  32. MILAKI G, Messaritakis I, Koinis F, Kotsakis A, et al
    Prognostic value of chemotherapy-resistant CK19mRNA-positive circulating tumor cells in patients with advanced/metastatic non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 May 18. doi: 10.1007/s00280-017-3339.
    PubMed     Text format     Abstract available


  33. CHEN X, Liu L, Guo Z, Liang W, et al
    UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis.
    Cancer Chemother Pharmacol. 2017 May 13. doi: 10.1007/s00280-017-3306.
    PubMed     Text format     Abstract available


  34. OKUDA Y, Sato K, Sudo K, Hasegawa Y, et al
    Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival.
    Cancer Chemother Pharmacol. 2017;79:1013-1020.
    PubMed     Text format     Abstract available


    April 2017
  35. FUJIWARA T, Kenmotsu H, Naito T, Kawamura T, et al
    The incidence and risk factors of febrile neutropenia in chemotherapy-naive lung cancer patients receiving etoposide plus platinum.
    Cancer Chemother Pharmacol. 2017 Apr 28. doi: 10.1007/s00280-017-3324.
    PubMed     Text format     Abstract available


  36. NISHIJIMA-FUTAMI Y, Minami S, Futami S, Koba T, et al
    Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Apr 28. doi: 10.1007/s00280-017-3321.
    PubMed     Text format     Abstract available


  37. LAU YY, Gu W, Lin T, Viraswami-Appanna K, et al
    Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Apr 19. doi: 10.1007/s00280-017-3308.
    PubMed     Text format     Abstract available


  38. XIANG T, Kang X, Gong Z, Bai W, et al
    XPG genetic polymorphisms and clinical outcome of patients with advanced non-small cell lung cancer under platinum-based treatment: a meta-analysis of 12 studies.
    Cancer Chemother Pharmacol. 2017;79:791-800.
    PubMed     Text format     Abstract available


    March 2017
  39. WAKELEE HA, Gettinger S, Engelman J, Janne PA, et al
    A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Mar 28. doi: 10.1007/s00280-017-3283.
    PubMed     Text format     Abstract available


  40. JANG J, Kim HK, Cho BC, Lee KH, et al
    Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Mar 24. doi: 10.1007/s00280-017-3289.
    PubMed     Text format     Abstract available


  41. ZHOU J, Dong F, Cui F, Xu R, et al
    The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Mar 13. doi: 10.1007/s00280-017-3269.
    PubMed     Text format     Abstract available


  42. HATA A, Katakami N, Hattori Y, Tanaka K, et al
    Pemetrexed monotherapy for chemo-naive elderly (aged >/=80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003).
    Cancer Chemother Pharmacol. 2017 Mar 9. doi: 10.1007/s00280-017-3259.
    PubMed     Text format     Abstract available


  43. KASHIWABARA K, Semba H, Fujii S, Tsumura S, et al
    Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
    Cancer Chemother Pharmacol. 2017 Mar 3. doi: 10.1007/s00280-017-3261.
    PubMed     Text format     Abstract available


  44. MORCOS PN, Bogman K, Hubeaux S, Sturm-Pellanda C, et al
    Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies.
    Cancer Chemother Pharmacol. 2017;79:559-568.
    PubMed     Text format     Abstract available


    February 2017
  45. IMAI H, Kuwako T, Kaira K, Masuda T, et al
    Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Feb 6. doi: 10.1007/s00280-016-3232.
    PubMed     Text format     Abstract available


    January 2017
  46. SHIMIZU T, Yonesaka K, Hayashi H, Iwasa T, et al
    Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Jan 31. doi: 10.1007/s00280-016-3231.
    PubMed     Text format     Abstract available


  47. TABCHI S, Blais N, Campeau MP, Tehfe M, et al
    Single-center comparison of multiple chemotherapy regimens for concurrent chemoradiotherapy in unresectable stage III non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2017 Jan 12. doi: 10.1007/s00280-016-3226.
    PubMed     Text format     Abstract available


    December 2016
  48. KAIRA K, Tomizawa Y, Imai H, Sakurai R, et al
    Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    November 2016
  49. IMAI H, Kaira K, Naruse I, Hayashi H, et al
    Successful afatinib treatment of advanced non-small-cell lung cancer patients undergoing hemodialysis.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  50. GARRETT M, Taylor T, Mould DR, Amantea MA, et al
    Lack of effect of smoking status on axitinib pharmacokinetics in patients with non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  51. ZHAO J, Ye X, Xu Y, Chen M, et al
    EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  52. FUKAE M, Shiraishi Y, Hirota T, Sasaki Y, et al
    Population pharmacokinetic-pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    September 2016
  53. ODA N, Hotta K, Yoshioka H, Kudo K, et al
    Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    August 2016
  54. KUBO T, Fujiwara K, Hotta K, Okada T, et al
    A phase II study of topotecan and cisplatin with sequential thoracic radiotherapy in elderly patients with small-cell lung cancer: Okayama Lung Cancer Study Group 0102.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  55. ZANG H, Wang W, Fan S
    The role of microRNAs in resistance to targeted treatments of non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  56. MADAN A, Jones BS, Bordoni R, Saleh MN, et al
    Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  57. YAMADA K, Ichiki M, Takahashi K, Hisamatsu Y, et al
    A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    June 2016
  58. OKUMA Y, Hosomi Y, Takahashi S, Nakahara Y, et al
    A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  59. MIZOGUCHI K, Nakamura Y, Sano K, Sato S, et al
    Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  60. MATIKAS A, Kentepozidis Nu, Ardavanis A, Vaslamatzis M, et al
    Efficacy and tolerance of frontline bevacizumab-based chemotherapy for advanced non-small cell lung cancer patients: a multicenter, phase IV study of the Hellenic Oncology Research Group (HORG).
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  61. ZOU T, Yin J, Zheng W, Xiao L, et al
    Rho GTPases: RAC1 polymorphisms affected platinum-based chemotherapy toxicity in lung cancer patients.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    April 2016
  62. SEKINE A, Satoh H, Baba T, Ikeda S, et al
    Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  63. OZAWA Y, Akahori D, Koda K, Abe T, et al
    Distinctive impact of pre-existing interstitial lung disease on the risk of chemotherapy-related lung injury in patients with lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  64. GUPTA A, Hussein Z, Hassan R, Wustner J, et al
    Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection.
    Cancer Chemother Pharmacol. 2016;77:733-43.
    PubMed     Text format     Abstract available


    March 2016
  65. KUDO K, Hotta K, Bessho A, Nogami N, et al
    Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  66. KARAYAMA M, Inui N, Kusagaya H, Suzuki S, et al
    Changes in cross-sectional area of pulmonary vessels on chest computed tomography after chemotherapy in patients with advanced non-squamous non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  67. YOSHIBA S, Jansen M, Matsushima N, Chen S, et al
    Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  68. KONTOPODIS E, Kotsakis A, Kentepozidis N, Syrigos K, et al
    A phase II, open-label trial of bortezomib (VELCADE) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  69. YOSHIMURA Y, Kurasawa M, Yorozu K, Puig O, et al
    Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
    Cancer Chemother Pharmacol. 2016;77:623-8.
    PubMed     Text format     Abstract available


  70. LUKE JJ, LoRusso P, Shapiro GI, Krivoshik A, et al
    ASP9853, an inhibitor of inducible nitric oxide synthase dimerization, in combination with docetaxel: preclinical investigation and a Phase I study in advanced solid tumors.
    Cancer Chemother Pharmacol. 2016;77:549-58.
    PubMed     Text format     Abstract available


    February 2016
  71. TRAFALIS DT, Alifieris C, Stathopoulos GP, Sitaras N, et al
    Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  72. ZHANG Q, Sun T, Kang P, Qian K, et al
    Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    January 2016
  73. TAKAGI Y, Hosomi Y, Nagamata M, Watanabe K, et al
    Phase II study of oral vitamin B supplementation as an alternative to intramuscular injection for patients with non-small cell lung cancer undergoing pemetrexed therapy.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  74. HEO SJ, Jung I, Lee CK, Kim JH, et al
    A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  75. RAJAGOPALAN P, Alahmari KA, Elbessoumy AA, Balasubramaniam M, et al
    Biological evaluation of 2-arylidene-4, 7-dimethyl indan-1-one (FXY-1): a novel Akt inhibitor with potent activity in lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


  76. STROH M, Green M, Cha E, Zhang N, et al
    Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancer.
    Cancer Chemother Pharmacol. 2016.
    PubMed     Text format     Abstract available


    December 2015
  77. KUMAR R, Lu SK, Minchom A, Sharp A, et al
    A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


    November 2015
  78. ARBITRIO M, Di Martino MT, Barbieri V, Agapito G, et al
    Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis.
    Cancer Chemother Pharmacol. 2015.
    PubMed     Text format     Abstract available


  79. TOLCHER AW, LoRusso P, Arzt J, Busman TA, et al
    Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.
    Cancer Chemother Pharmacol. 2015;76:1025-32.
    PubMed     Text format     Abstract available


  80. MORGAN RJ, Synold TW, Longmate JA, Quinn DI, et al
    Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.
    Cancer Chemother Pharmacol. 2015;76:897-907.
    PubMed     Text format     Abstract available


    September 2015
  81. MLAK R, Krawczyk P, Ciesielka M, Homa I, et al
    Predictive value of STMN1 gene promoter polymorphism (-2166T>C) in patients with advanced NSCLC treated with the combination of platinum compounds and vinorelbine.
    Cancer Chemother Pharmacol. 2015;76:621-9.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: